SuspendedPHASE1, PHASE2NCT05419479
Switch Maintenance in Pancreatic
Studying Squamous cell carcinoma of pancreas
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- James Cleary, MD, PhD
- Principal Investigator
- James Cleary, MD, PhDDana-Farber Cancer Institute
- Intervention
- ZIMBERELIMAB(drug)
- Enrollment
- 46 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2028
Study locations (1)
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
Collaborators
Arcus Biosciences, Inc. · Lustgarten Foundation
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05419479 on ClinicalTrials.govOther trials for Squamous cell carcinoma of pancreas
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07172802A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid TumorsGI Innovation, Inc.
- ACTIVE NOT RECRUITINGPHASE2NCT05945823Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid TumorsTaiho Oncology, Inc.